GO:0071670 smooth muscle cell chemotaxis: Vascular Remodeling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071670 (smooth muscle cell chemotaxis) is the biological process of directed smooth muscle cell migration along an external chemical gradient.
• It is a hallmark of vascular remodeling in atherosclerosis, where vascular smooth muscle cells (VSMCs) migrate from the media into the intima.
• GAS6-AXL signaling is a defined chemotactic axis for VSMCs, and dyslipidemia modulates thrombospondin-1-induced VSMC chemotaxis [5,6].
• In asthma, airway smooth muscle cells can attract mast cells through secreted ATP after Th2 cytokine priming, showing smooth muscle cells can also be the source of chemotactic signals.
• Eosinophil-derived 14-HDHA and 17-HDHA protect against pulmonary hypertension, illustrating that lipid mediators shape smooth muscle cell recruitment in the lung vasculature.
• CRISPR knockout, knock-in, point-mutation and overexpression models allow causal testing of candidate chemotaxis genes in smooth muscle cells.
Description
GO:0071670, smooth muscle cell chemotaxis, is the biological process in which a smooth muscle cell moves in a directed manner in response to an external stimulus. Unlike random motility, chemotaxis requires a gradient-sensing machinery that converts extracellular cues into polarized actin dynamics and forward propulsion, and it is a central mechanism by which smooth muscle cells relocate during development, repair and disease. In the vessel wall, this process underlies the migration of vascular smooth muscle cells (VSMCs) from the tunica media into the intima, a step that contributes to atherosclerotic plaque formation and neointimal thickening. Because smooth muscle cells are not terminally fixed in place, their chemotactic behavior is now recognized as a therapeutic and experimental target in vascular biology. The process is also relevant outside the vasculature: in the airway, smooth muscle cells participate in inflammatory cell recruitment, and Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP. In the pulmonary circulation, eosinophil-derived lipid mediators 14-HDHA and 17-HDHA protect against pulmonary hypertension, a setting in which smooth muscle cell behavior is central. Together these observations show that smooth muscle cell chemotaxis is a context-dependent process driven by growth factors, lipid mediators, extracellular matrix proteins and inflammatory signals [1,2,5,6,8]. For researchers, GO:0071670 provides a precise annotation target for functional genomics: it allows candidate genes to be tested for causal roles in directed smooth muscle cell migration rather than in proliferation or apoptosis alone [2,5,6].
smooth muscle cell chemotaxis At A Glance
| GO ID | GO:0071670 |
|---|---|
| GO term | smooth muscle cell chemotaxis |
| Ontology | biological_process |
| Synonym | none listed |
| Definition | The directed movement of a smooth muscle cell in response to an external stimulus. |
| Major function | Directed migration of smooth muscle cells along chemical gradients during vascular remodeling, inflammation and repair. |
| Cell type | Smooth muscle cells, including vascular smooth muscle cells and airway smooth muscle cells [2,8]. |
| Representative cues | GAS6, thrombospondin-1, ATP and lipid mediators such as 14-HDHA and 17-HDHA [1,5,6,8]. |
| Disease relevance | Atherosclerosis, pulmonary hypertension and asthma-related airway remodeling [1,2,3,8]. |
What Is GO:0071670?
In plain terms, GO:0071670 describes the directed movement of a smooth muscle cell in response to an external stimulus. The cell senses a chemical gradient, becomes polarized, and moves toward or away from the stimulus source. This is distinct from general cell motility because directionality is imposed by the external cue, and it is distinct from proliferation or differentiation because the output is cell displacement.
Why Is smooth muscle cell chemotaxis Important in Cell Biology?
Smooth muscle cell chemotaxis matters because it converts soluble signals into structural changes in tissues. In atherosclerosis, VSMC migration from the media to the intima is a defining event in plaque development and vascular remodeling. In the lung, mediators that influence smooth muscle recruitment can alter pulmonary vascular tone and remodeling, as shown by the protective effects of eosinophil-derived 14-HDHA and 17-HDHA in pulmonary hypertension. In asthma, the interaction between airway smooth muscle and mast cells depends on chemotactic signals such as ATP, linking smooth muscle biology to airway inflammation [3,8]. Because these processes are druggable and genetically tractable, GO:0071670 is a high-value annotation for target discovery and for interpreting functional genomics screens in vascular and airway disease [2,5,6].
• Defines the directed migration step that drives VSMC accumulation in atherosclerotic plaques.
• Provides a mechanistic framework for neointimal hyperplasia after vascular injury.
• Links lipid mediators such as 14-HDHA and 17-HDHA to pulmonary vascular protection.
• Explains how airway smooth muscle cells can recruit mast cells in asthma via ATP.
• Identifies GAS6-AXL as a ligand-receptor axis for VSMC chemotaxis.
• Shows that dyslipidemia modulates thrombospondin-1-induced VSMC chemotaxis.
• Supports functional genomics by giving a defined phenotype for CRISPR screens [2,5,6].
• Connects smooth muscle behavior to inflammatory cell infiltration in vascular and airway tissues [3,7,8].
• Offers a measurable endpoint for testing anti-remodeling therapeutics [1,2].
• Enables cross-disease comparison of chemotactic cues across vascular and respiratory systems [1,2,3,8].
What Happens During smooth muscle cell chemotaxis?
Gradient sensing and receptor activation
In simple terms: The cell first detects a chemical signal outside itself.
Smooth muscle cell chemotaxis begins when extracellular cues bind surface receptors. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells, establishing a ligand-receptor axis that directly drives directed migration. Thrombospondin-1 also induces VSMC chemotaxis, and this response is regulated by the lipid environment, since dyslipidemia modulates thrombospondin-1-induced vascular smooth muscle cell chemotaxis. In the airway, Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP, showing that smooth muscle cells can both respond to and generate chemotactic signals.
Polarization and cytoskeletal rearrangement
In simple terms: The cell reorganizes its skeleton so it can move in one direction.
After receptor activation, the smooth muscle cell must break symmetry and establish a leading edge. This step converts gradient information into directed force production and is the defining feature that separates chemotaxis from random motility. In vascular smooth muscle cells, this migratory program is part of the phenotypic switching that allows medial cells to move into the intima during atherosclerosis. The process is therefore not simply contraction but a coordinated motile program.
Directed migration and matrix interaction
In simple terms: The cell crawls through its surroundings toward the signal.
Directed movement requires adhesion to and remodeling of the surrounding matrix. In atherosclerosis, VSMC migration through the vessel wall is a key step in plaque formation, and the cells must navigate a complex extracellular environment. Thrombospondin-1 provides one such matrix-linked chemotactic cue, and its effect on VSMC chemotaxis is sensitive to dyslipidemia. This stage links soluble signals to tissue-level remodeling [2,5].
Integration with inflammation and lipid mediators
In simple terms: Other cells and fats in the body can tune how strongly smooth muscle cells move.
Smooth muscle cell chemotaxis does not occur in isolation. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA, indicating that lipid mediators derived from inflammatory cells influence smooth muscle behavior in the pulmonary vasculature. In asthma, mast cell migration to airway smooth muscle is a chemotactic interaction relevant to disease, and blocking the attraction is considered a therapeutic goal. Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation, further showing that smooth muscle biology is embedded in inflammatory networks.
Outcomes in tissue remodeling
In simple terms: The final result is a change in where smooth muscle cells sit in the tissue.
The endpoint of smooth muscle cell chemotaxis is repositioning of smooth muscle cells within a tissue, which can alter vessel wall structure, airway wall composition and pulmonary vascular remodeling [1,2,3]. In atherosclerosis, this repositioning contributes to intimal thickening. In pulmonary hypertension, mediators that modulate this process can be protective. In asthma, smooth muscle-derived signals recruit mast cells, linking smooth muscle chemotaxis to airway inflammation [3,8].
Key Genes Involved in GO:0071670 smooth muscle cell chemotaxis
The following genes and proteins have documented roles in smooth muscle cell chemotaxis or in the chemotactic interactions of smooth muscle cells with other cell types.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAS6 | Ligand that induces Axl-mediated chemotaxis of vascular smooth muscle cells | Direct chemotactic cue for VSMC migration assays |
| AXL | Receptor tyrosine kinase mediating GAS6-induced VSMC chemotaxis | Receptor-side target for blocking VSMC migration |
| THBS1 | Thrombospondin-1 induces VSMC chemotaxis and is modulated by dyslipidemia | Matrix-linked chemotactic cue in atherosclerosis models |
| NPY | Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation | Links neuroimmune signaling to smooth muscle phenotype |
| ATP (extracellular) | Secreted by Th2 cytokine-primed airway smooth muscle cells to induce mast cell chemotaxis | Metabolic signal in airway smooth muscle-mast cell crosstalk |
| 14-HDHA | Eosinophil-derived lipid mediator that protects against pulmonary hypertension | Lipid mediator influencing pulmonary vascular smooth muscle biology |
| 17-HDHA | Eosinophil-derived lipid mediator that protects against pulmonary hypertension | Lipid mediator influencing pulmonary vascular smooth muscle biology |
| Mast cell mediators | Mast cell migration to airway smooth muscle in asthma | Readout of smooth muscle-derived chemotactic signals |
| VSMC contractile markers | Markers of the differentiated state that is lost during migratory phenotypic switching | Used to distinguish contractile from migratory VSMC states |
| Inflammatory cytokines (Th2) | Prime airway smooth muscle cells to induce mast cell chemotaxis | Upstream regulators of smooth muscle chemotactic signaling |
| Eosinophil products | Source of 14-HDHA and 17-HDHA in pulmonary hypertension protection | Cell source for lipid-mediated smooth muscle modulation |
| Macrophage recruitment factors | Linked to neuropeptide Y-driven endothelial dysfunction and smooth muscle foam cell formation | Connects smooth muscle phenotype to innate immunity |
How Is smooth muscle cell chemotaxis Regulated?
Smooth muscle cell chemotaxis is regulated at multiple levels. The lipid environment modulates the response, as dyslipidemia regulates thrombospondin-1-induced vascular smooth muscle cell chemotaxis. Receptor-ligand availability controls the strength of the signal, exemplified by GAS6-induced Axl-mediated chemotaxis. Inflammatory priming regulates the ability of smooth muscle cells to generate chemotactic signals, since Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via ATP secretion. Lipid mediators from eosinophils, including 14-HDHA and 17-HDHA, can protect against pulmonary hypertension, indicating that endogenous lipid signals shape smooth muscle behavior in the lung. Neuropeptide Y elevation in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation, adding a neuroimmune layer of regulation.
smooth muscle cell chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GAS6 | Atherosclerosis and VSMC chemotaxis | VSMC knockout of GAS6 or AXL with chemotaxis assay |
| AXL | VSMC chemotaxis and vascular remodeling | AXL point-mutation or knockout VSMC line |
| THBS1 | Dyslipidemia-modulated VSMC chemotaxis | THBS1 overexpression in VSMC under lipid-loaded conditions |
| NPY | Endothelial dysfunction, macrophage infiltration and smooth muscle foam cell formation | NPY overexpression or knockout in endothelial-smooth muscle co-culture |
| Eosinophil lipid mediators | Pulmonary hypertension protection | 14-HDHA/17-HDHA treatment in pulmonary vascular smooth muscle models |
Atherosclerosis and vascular remodeling
Vascular smooth muscle cell migration from the media to the intima is a central event in atherosclerosis, and the chemotactic behavior of these cells contributes to plaque formation and vessel wall remodeling. Thrombospondin-1-induced VSMC chemotaxis is modulated by dyslipidemia, directly linking lipid status to smooth muscle migration in atherosclerotic disease. GAS6-AXL signaling provides a defined chemotactic axis that can be targeted to study VSMC recruitment. Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation, further connecting smooth muscle chemotaxis to atherosclerotic lesion biology.
Pulmonary hypertension
Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA, identifying lipid mediators that influence pulmonary vascular smooth muscle biology. Because smooth muscle cell chemotaxis contributes to vascular remodeling, these mediators provide a mechanistic link between inflammation and pulmonary vascular protection.
Asthma and airway remodeling
Mast cell migration to airway smooth muscle is a recognized feature of asthma, and blocking this attraction is a therapeutic concept. Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP, providing a concrete mechanism for smooth muscle-driven inflammatory cell recruitment in the airway. This places smooth muscle cell chemotaxis within the broader framework of asthma-related airway remodeling [3,8].
From smooth muscle cell chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is GAS6-AXL required for VSMC chemotaxis? | AXL knockout VSMC line with GAS6 gradient assay |
| Does dyslipidemia change thrombospondin-1-induced chemotaxis? | THBS1 overexpression VSMC under lipid-loaded conditions |
| Can airway smooth muscle-derived ATP recruit mast cells? | Th2 cytokine-primed airway smooth muscle cells with mast cell migration assay |
| Do lipid mediators protect pulmonary vascular smooth muscle? | 14-HDHA/17-HDHA treatment in pulmonary hypertension models |
| Does neuropeptide Y drive smooth muscle foam cell formation? | NPY overexpression or knockout in endothelial-smooth muscle co-culture |
| Which genes are causal for smooth muscle chemotaxis? | CRISPR knockout library screen in primary smooth muscle cells |
How to Study the smooth muscle cell chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Directed migration toward a gradient | Testing GAS6-AXL and thrombospondin-1 effects on VSMC [5,6] |
| Microfluidic gradient device | Real-time directional movement | Quantifying chemotactic efficiency of smooth muscle cells |
| Co-culture migration assay | Chemotaxis of one cell type induced by another | Airway smooth muscle-induced mast cell chemotaxis via ATP |
| CRISPR knockout | Loss-of-function effect on chemotaxis | Testing candidate genes for causal roles |
| CRISPR knock-in / point mutation | Effect of specific variants or tags | Dissecting receptor domains such as AXL |
| Overexpression | Gain-of-function effect on chemotaxis | Testing THBS1 or NPY in smooth muscle models [5,7] |
| Lipid mediator treatment | Effect of 14-HDHA/17-HDHA on vascular cells | Pulmonary hypertension protection studies |
| Histology and imaging | Tissue-level smooth muscle repositioning | Atherosclerosis and airway remodeling models [2,3] |
Transwell and microfluidic chemotaxis assays
Directed migration of smooth muscle cells is typically measured using gradient-based assays. These assays are the direct functional readout for GO:0071670 and have been used to define GAS6-induced Axl-mediated VSMC chemotaxis and thrombospondin-1-induced VSMC chemotaxis under dyslipidemic conditions [5,6]. They can be combined with genetic perturbation to test causality [5,6].
Co-culture and conditioned-medium experiments
Because smooth muscle cells can both respond to and produce chemotactic signals, co-culture systems are valuable. Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via ATP secretion, a finding obtained with conditioned-medium and co-culture approaches. Similar designs can test whether eosinophil-derived mediators such as 14-HDHA and 17-HDHA alter pulmonary vascular smooth muscle behavior.
Genetic perturbation with CRISPR
CRISPR knockout, knock-in, point-mutation and overexpression models allow candidate genes to be tested for causal roles in smooth muscle cell chemotaxis. This is essential because observational associations, such as the link between neuropeptide Y and smooth muscle foam cell formation, require functional validation. CRISPR screens can also nominate new regulators of the process.
In vivo vascular and airway models
Animal and tissue models of atherosclerosis, pulmonary hypertension and asthma provide the physiological context for chemotaxis findings [1,2,3]. These models connect in vitro migration data to tissue-level outcomes such as intimal thickening and airway inflammation [1,2,3].
How CRISPR Can Be Used to Study GO:0071670 smooth muscle cell chemotaxis
Knockout
CRISPR knockout of candidate genes such as AXL or GAS6 in smooth muscle cells allows direct testing of whether the GAS6-AXL axis is required for chemotaxis. Knockout of THBS1 or its regulators can clarify how thrombospondin-1-induced VSMC chemotaxis is controlled under dyslipidemic conditions. Knockout screens can also nominate new genes for GO:0071670.
Point Mutation
Point mutations can be introduced into receptor genes such as AXL to map the domains required for GAS6-induced chemotaxis. This approach is useful when a complete knockout is lethal or when a specific signaling residue is suspected to control directed migration.
Knock-in
Knock-in of tagged or reporter alleles allows endogenous expression of chemotaxis-related genes to be monitored in smooth muscle cells. This is valuable for tracking genes such as NPY or THBS1 in co-culture and tissue models [5,7].
Overexpression
Overexpression of THBS1 or NPY in smooth muscle or endothelial cells can test gain-of-function effects on chemotaxis and foam cell formation [5,7]. Overexpression of lipid mediator pathways can also be used to study pulmonary vascular protection by 14-HDHA and 17-HDHA.
How EDITGENE Supports smooth muscle cell chemotaxis Research
Researchers studying smooth muscle cell chemotaxis-related genes often need to determine whether a candidate gene is causally involved in directed migration or is merely correlated with vascular and airway disease phenotypes. EDITGENE provides the CRISPR tools and cell models needed to move from association to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for smooth muscle cell chemotaxis research.
Frequently Asked Questions About smooth muscle cell chemotaxis
What is GO:0071670?
GO:0071670 is the Gene Ontology biological process term for smooth muscle cell chemotaxis, defined as the directed movement of a smooth muscle cell in response to an external stimulus.
What is smooth muscle cell chemotaxis?
It is the process by which a smooth muscle cell senses a chemical gradient and moves directionally toward or away from the signal source.
What genes are involved in smooth muscle cell chemotaxis?
Documented genes and proteins include GAS6 and AXL, which mediate VSMC chemotaxis, and THBS1, which induces VSMC chemotaxis under dyslipidemic regulation [5,6].
How is smooth muscle cell chemotaxis measured?
It is commonly measured with Transwell or microfluidic gradient assays, and can be combined with CRISPR perturbation to test causality [5,6].
Why is smooth muscle cell chemotaxis important in atherosclerosis?
VSMC migration from the media to the intima is a key step in atherosclerotic plaque formation and vascular remodeling.
Does dyslipidemia affect smooth muscle cell chemotaxis?
Yes, dyslipidemia regulates thrombospondin-1-induced vascular smooth muscle cell chemotaxis.
What is the role of GAS6-AXL in smooth muscle cell chemotaxis?
GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells, defining a ligand-receptor axis for directed migration.
How do airway smooth muscle cells interact with mast cells?
Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP.
What lipid mediators affect pulmonary vascular smooth muscle?
Eosinophil-derived 14-HDHA and 17-HDHA protect against pulmonary hypertension and influence pulmonary vascular biology.
How can CRISPR help study smooth muscle cell chemotaxis?
CRISPR knockout, knock-in, point-mutation and overexpression models allow causal testing of candidate genes in chemotaxis assays [2,5,6].
Conclusion
GO:0071670, smooth muscle cell chemotaxis, is a defined biological process that links extracellular chemical cues to directed smooth muscle cell migration. Its importance spans atherosclerosis, pulmonary hypertension and asthma, where smooth muscle repositioning and smooth muscle-derived signals shape disease [1,2,3,8]. Key molecular players include GAS6-AXL and thrombospondin-1, and the process is modulated by lipids and inflammatory mediators [1,5,6,7,8]. CRISPR-based models provide a direct route to test which genes are causal for this process, making GO:0071670 a practical annotation for vascular and airway research [2,5,6].
References
- 1. Shu T et al.. 2023. Eosinophils protect against pulmonary hypertension through 14-HDHA and 17-HDHA.. Eur Respir J 61(3) PMID: 36423907
- 2. Chistiakov DA et al.. 2015. Vascular smooth muscle cell in atherosclerosis.. Acta Physiol (Oxf) 214(1):33-50 PMID: 25677529
- 3. Lagan AL et al.. 2014. Mast cell migration to airway smooth muscle in asthma. Can we Gro(w) something to block the attraction?. Clin Exp Allergy 44(3):302-3 PMID: 24588862
- 5. Desai P et al.. 2015. Dyslipidemia regulates thrombospondin-1-induced vascular smooth muscle cell chemotaxis.. Mol Cell Biochem 410(1-2):85-91 PMID: 26350564
- 6. Fridell YW et al.. 1998. GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells.. J Biol Chem 273(12):7123-6 PMID: 9507025
- 7. Choi B et al.. 2019. Elevated Neuropeptide Y in Endothelial Dysfunction Promotes Macrophage Infiltration and Smooth Muscle Foam Cell Formation.. Front Immunol 10:1701 PMID: 31379881
- 8. Gao YD et al.. 2014. Th2 cytokine-primed airway smooth muscle cells induce mast cell chemotaxis via secretion of ATP.. J Asthma 51(10):997-1003 PMID: 25272186
